{"title": "Canal SEMI COVID-19 para Profesionales", "author": null, "url": "https://www.fesemi.org/canal-semi-para-profesionales-covid-19", "hostname": "fesemi.org", "description": null, "sitename": "fesemi.org", "date": "2020-04-17", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Canal SEMI COVID-19 para Profesionales\nBienvenido/a al canal COVID-19 para profesionales de la Sociedad Espa\u00f1ola de Medicina Interna (SEMI).\nEste espacio pretende servir de punto de encuentro entre internistas para compartir informaci\u00f3n sobre el coronavirus, as\u00ed como para plantear consultas e intercambiar datos que puedan ser de utilidad al conjunto de los profesionales de la SEMI en estos momentos.\nAdem\u00e1s de poder compartir documentos, protocolos, an\u00e1lisis e impresiones, a trav\u00e9s de los siguientes enlaces puedes acceder a:\n-\n[informaci\u00f3n en tiempo real de la evoluci\u00f3n de la emergencia sanitaria declarada en Espa\u00f1a por el COVID-19](https://covid19.isciii.es/) (por CC.AA.)\n-\n[documentos t\u00e9cnicos](https://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos.htm) del Ministerio de Sanidad para profesionales sanitarios.\n-\u00faltimos\n[informes diarios](http://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx) sobre la pandemia en Espa\u00f1a del Instituto de Salud Carlos III (ISCIII).\nEste canal nos permitir\u00e1 estar coordinados e informados sobre todo lo relacionado con el coronavirus (Covid-19).\nA trav\u00e9s de estos enlaces, podr\u00e1 acceder a los canales de\n[The New England Journal of Medicine](https://lnkd.in/eCqwmu6), [The BMJ](https://www.bmj.com/<span class='finded'>coronavirus), [The Lancet](https://lnkd.in/ecvvMH9), y [JAMA.](https://lnkd.in/eAHguDq)\nAdem\u00e1s, puedes acceder en abierto, a la edici\u00f3n en espa\u00f1ol del\n[mini-manual de Kamps&Hoffman sobre COVID-19](https://covidreference.com/es) con informaci\u00f3n recopilada sobre epidemiolog\u00eda, virolog\u00eda, inmunolog\u00eda, diagn\u00f3stico y manifestaci\u00f3n cl\u00ednica de la enfermedad por SARS-CoV-2, entre otros muchos aspectos. Edici\u00f3n del 29 de marzo de 2020.\nPara acceder a todas las funcionalidades de est\u00e1 p\u00e1gina, recuerde que deber\u00e1 estar identificado en la web con sus credenciales de socio de SEMI (usuario y contrase\u00f1a).\n[ACCEDE AL FORO PARA PROFESIONALES DE SEMI](https://www.fesemi.org/foros/canal-profesional-covid-19-semi)\nDocumentos t\u00e9cnicos, protocolos y esquemas terap\u00e9uticos recopilados por SEMI y sus entidades miembro sobre COVID-19.\n-DOCUMENTOS OFICIALES: MINISTERIOS, COMUNIDADES AUT\u00d3NOMAS (CC.AA.) Y OTROS ORGANISMOS DE LA ADMINISTRACI\u00d3N\nActualizaci\u00f3n de la Estrategia de Vacunaci\u00f3n frente a COVID-19. Preguntas y respuestas frecuentes. Abril de 2021\nUna visi\u00f3n global de la pandemia COVID-19: qu\u00e9 sabemos y qu\u00e9 estamos investigando desde el CSIC\nEstudio ENE-COVID19: Infome final. Estudio Nacional de Sero-epidemiolog\u00eda de la infecci\u00f3n por SARS-CoV-2 en Espa\u00f1a. 6 de julio de 2020\nEstudio ENE-COVID19: Segunda ronda Estudio Nacional de Sero-epidemiolog\u00eda de la infecci\u00f3n por SARS-CoV-2 en Espa\u00f1a. Informe preliminar a fecha 3 de junio de 2020\nClinical Management of COVID-19. OMS-WHO. 27 de mayo de 2020\nSospechas de reacciones adversas notificadas con tratamientos utilizados en COVID-19\nTratamientos disponibles para el manejo de la infecci\u00f3n respiratoria por SARS-CoV-2\nInformaci\u00f3n Cient\u00edfico-T\u00e9cnica. Enfermedad por Coronavirus COVID-19. Actualizaci\u00f3n a 18 de mayo de 2020\nEstudio ENE-COVID19: Primera ronda Estudio Nacional de Sero-epidemiolog\u00eda de la infecci\u00f3n por SARS-CoV-2 en Espa\u00f1a. Informe Preliminar a fecha 13 de mayo de 2020\nInforme sobre la situaci\u00f3n de COVID-19 en Espa\u00f1a. 7 de mayo de 2020\nEstrategia de Diagn\u00f3stico, vigilancia y control en la fase de transici\u00f3n de la pandemia de COVID-19. Indicadores de seguimiento. 6 de mayo de 2020\nCoronavirus Disease 2019 (COVID-19). Medical Virology: from Pathogenesis to Disease Control\nCOVID-19. Recomendaciones sanitarias para la estrategia de transici\u00f3n. CCAES. Ministerio Sanidad. 25 de abril de 2020\nCloroquina/Hidroxicloroquina: precauciones y vigilancia de posibles reacciones adversas en pacientes con COVID-19.22.04.20\nInterpretaci\u00f3n de las pruebas diagn\u00f3sticas frente a SARS-CoV-2. 22 de abril de 2020\nCoronavirus disease 2019 (COVID-19) Situation Report \u2013 84. OMS.\nInstrucciones de la AEMPS para el uso compasivo de Tocilizumab (TCZ)\nPrevenci\u00f3n y control de la infecci\u00f3n en el manejo de pacientes con COVID-19. Versi\u00f3n 14 de abril\nEPICOS - Ensayo Cl\u00ednico para la Prevenci\u00f3n de la Infecci\u00f3n por Coronavirus en Sanitarios\nGu\u00eda para la utilizaci\u00f3n de test r\u00e1pidos de anticuerpos para COVID-19. Ministerio de Sanidad\nCOVID-19. EU recommendations for testing strategies. Comisi\u00f3n Europea.\nLa AEMPS informa sobre el buen uso de medicamentos relacionados con COVID-19\nGu\u00eda para la utilizaci\u00f3n de test diagn\u00f3sticos para COVID-19. 6 de abril de 2020\nInformaci\u00f3n Cient\u00edfica-T\u00e9cnica. Enfermedad por Coronavirus (COVID-19). Actualizaci\u00f3n, 4 de abril de 2020\nProcedimientos de actuaci\u00f3n frente al COVID-19 en Asturias. Protocolo general. 1 de abril\nProcedimiento de actuaci\u00f3n frente a casos de infecci\u00f3n por el nuevo Coronavirus SARS-CoV-2. Actualizado a 31 de marzo\nGu\u00eda de actuaci\u00f3n frente a COVID-19 en los profesionales sanitarios y sociosanitarios. Versi\u00f3n 31 de marzo\nRecomendaciones de la AEMPS para la gesti\u00f3n de medicamentos para el manejo de pacientes en fase terminal\nRecomendaciones para el manejo, prevenci\u00f3n y control de COVID-19 en Unidades de Di\u00e1lisis. Versi\u00f3n de 25 de marzo de 2020\nProcedimiento de actuaci\u00f3n para los servicios de prevenci\u00f3n de riesgos laborales frente a la exposici\u00f3n al SARS\u2010CoV\u20102. 30 de marzo de 2020\nInforme del Comit\u00e9 de Bio\u00e9tica de Espa\u00f1a sobre los aspectos bio\u00e9ticos de la priorizaci\u00f3n de recursos sanitarios en el contexto de la crisis del coronavirus\nInforme sobre la incidencia del COVID-19 en Espa\u00f1a. Actualizaci\u00f3n n\u00famero 57. Ministerio de Sanidad. CCAES.\nInformaci\u00f3n Cient\u00edfico-T\u00e9cnica de la enfermedad por Coronavirus COVID-19. CCAES. Ministerio de Sanidad. Actualizaci\u00f3n 26 de marzo de 2020\nTratamientos disponibles para el manejo de la infecci\u00f3n respiratoria por SARS-CoV-2. AEMPS. 26 de marzo\nManejo cl\u00ednico del COVID-19: tratamiento m\u00e9dico. Ministerio de Sanidad\nLa AEMPS informa de la distribuci\u00f3n controlada de todo el stock de hidroxicloroquina-cloroquina\nGu\u00eda de prevenci\u00f3n y control frente al COVID-19 en residencias de mayores y otros centros de servicios sociales de car\u00e1cter residencial\nActualizaci\u00f3n N\u00ba 52. Enfermedad por el coronavirus (COVID-19). 22.03.2020\nInforme Fake News y desinformaciones sobre el virus COVID-19 en fuentes abiertas\nProtocolo de derivaci\u00f3n de pacientes con COVID-19 a hoteles sanitarizados de la Comunidad de Madrid.\nManejo cl\u00ednico del COVID-19: atenci\u00f3n hospitalaria\nManejo de la mujer embarazada y el reci\u00e9n nacido con COVID-19\nProcedimiento de atenci\u00f3n y seguimiento domiciliario de casos posibles y confirmados por SARS-CoV-2 (COVID-19)\nToma y preparaci\u00f3n de las muestras biol\u00f3gicas en domicilio en casos en investigaci\u00f3n por SARS-CoV-2\nMedicamentos antihipertensivos que act\u00faan sobre el sistema renina angiotensina e infecci\u00f3n por COVID-19\nLa AEMPS informa que ning\u00fan dato indica que el ibuprofeno agrave las infecciones por COVID-19\nGu\u00eda de actuaci\u00f3n con los profesionales sanitarios en el caso de exposiciones de riesgo a COVID-19 en el \u00e1mbito sanitario\nBolet\u00edn Oficial del Estado (BOE). 15 de marzo de 2020.\n-EPIDEMIOLOG\u00cdA, TRANSMISI\u00d3N Y PATOG\u00c9NESIS:\nVirology, transmission, and pathogenesis of SARS-CoV-2\nNatural History of Asymptomatic SARS-CoV-2 Infection\nCOVID-19: from epidemiology to treatment\nImbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19\nCOVID-19 infection: Origin, transmission, and characteristics of human coronaviruses\nTail risk of contagious diseases\nNovel viruses, old data, and basic principles: how to save lives and avoid harm amid the unknown\nContact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset\nEpidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers\nBCG-induced trained immunity: can it offer protection against COVID-19?\nCOVID-19 and Postinfection Immunity\nChanges in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020\nSARS-COV-2 was already spreading in France in late December 2019\nA cohort of patients with COVID-19 in a major teaching hospital in Europe\nThe Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application\nDeath and dying during the pandemic\nSubstantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)\nThis Time Must Be Different: Disparities During the COVID-19 Pandemic\nCOVID-19 Epidemic: Exercise or Not to Exercise; That is the Question!\nImpact of contact tracing on SARS-CoV-2 transmission\nIs temperature reducing the transmission of COVID-19?\nRespiratory virus shedding in exhaled breath and efficacy of face masks\nPresymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility\nAsymptomatic Transmission, the Achilles\u2019 Heel of Current Strategies to Control Covid-19\nGlobal Virology III: Virology in the 21st Century\nThe convalescent sera option for containing COVID-19\nProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science.\nMeeting the Care Needs of Older Adults Isolated at HomeDuring the COVID-19 Pandemic\nImpact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study\nCovid-19 and Immunity in Aging Populations \u2014 A New Research Agenda\nSpread of SARS-CoV-2 in the Icelandic Population\nCOVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020\nTemporal dynamics in viral shedding and transmissibility of COVID-19\nProjecting the transmission dynamics of SARS-CoV-2 through the postpandemic period\nThe Mental Health Consequences of COVID-19 and Physical Distancing\nA Sneeze\nCoronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy\nQuarantine alone or in combination with other public health measures to control COVID-19: a rapid review (Review)\nGuidance for discharge and ending isolation in the context of widespread community transmission of COVID-19 \u2013 first update. ECDC.\nMolecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes\nCovid-19: Why Germany\u2019s case fatality rate seems so low\nThe Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application\nQuantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing\nEarly dynamics of transmission and control of COVID-19: a mathematical modelling study\nCOVID-19 Science Report: Containment Measures\nFirst known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA\nTen Weeks to Crush the Curve\nModelizaci\u00f3n Epidemiol\u00f3gica del Covid-19 para Espa\u00f1a\nEvidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host\u2212Virus Interaction, and Proposed Neurotropic Mechanisms\nThe outbreak of COVID-19: An overview\nCOVID-19: Gastrointestinal manifestations and potential fecal-oral transmission\nPreliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 \u2014 United States\nTimely research papers about COVID-19 in China\nThe SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?\nResponding to the COVID-19 pandemic in complex humanitarian crises\nPatients with respiratory symptoms are at greater risk of COVID-19 transmission\nCanadian Geriatrics Society COVID-19 Recommendations for Older Adults.What Do Older Adults Need To Know?\nSARS-CoV-2 Infection in Children\nMass masking in the COVID-19 epidemic: people need guidance\nHow will country-based mitigation measures influence the course of the COVID-19 epidemic?\nSARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Revista Cell\nEarly Transmission Dynamics in Wuhan, China, of Novel Coronavirus\u2013Infected Pneumonia\nCOVID-19: Una propuesta de estadificaci\u00f3n cl\u00ednico-terap\u00e9utica. Journal of Heart and Lung Transplantation\nReport sulle caratteristiche dei pazienti deceduti positivi a COVID-19 in Italia Il presente report \u00e8 basato sui dati ggiornati al 13 Marzo 2020\nCOVID-19 and Italy: what next?\nPersistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents\nAerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. TNEJM\n2019 novel coronavirus patients\u2019 clinical characteristics, discharge rate and fatality rate of meta-analysis\nCoronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ\nContamination of healthcare workers\u2019 mobile phones by epidemic viruses. CMI\nNational UK programme of community health workers for COVID-19 response\nThe origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak \u2013 an update on the status. MMR\nSubstantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)\nProtocolo de ventilaci\u00f3n m\u00faltiple con un solo ventilador para situaciones de pandemia-cat\u00e1strofe sanitaria\nCoronavirus Disease 2019 (COVID-19) in Italy. JAMA Infographic\nComunicado de la Sociedad Espa\u00f1ola de Neurolog\u00eda (SEN) sobre la enfermedad por COVID-19.\n-PREVENCI\u00d3N Y VACUNACI\u00d3N:\nRecomendaciones para el diagn\u00f3stico y tratamiento de eventos tromb\u00f3ticos tras la vacunaci\u00f3n frente a la COVID-19. Documento FACME actualizado a fecha 4 de junio (versi\u00f3n 5). Disponible, aqu\u00ed\nSobre las condiciones de riesgo alto de padecer enfermedad grave por COVID-19 y las decisiones de priorizaci\u00f3n de la vacunaci\u00f3n (FACME)\nSafety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial\nCollaborative delirium prevention in the age of COVID-19\nEstimating the effects of non-pharmaceutical interventions on COVID-19 in Europe\nPhysical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis\nRoutine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019\nCoronavirus Disease 2019 (COVID-2019) Infection Among Health Care Workers and Implications for Prevention Measures in a Tertiary Hospital in Wuhan, China\nMoving Personal Protective Equipment Into the Community Face Shields and Containment of COVID-19\nHypertension and COVID-19\nSafety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial\nII Informe OMC Comisi\u00f3n Asesora COVID-19 sobre uso mascarillas en \u00e1mbito sanitario y poblaci\u00f3n general\nChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques\nSARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults\nSARS-CoV-2 Vaccines: Status Report\nThe First, Comprehensive Immunological Model of COVID-19: Implications for Prevention, Diagnosis, and Public Health Measures\nClinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy\nDeveloping Covid-19 Vaccines at Pandemic Speed\nAdvice on the use of masks in the context of COVID-19\nVitamin D supplementation could prevent and treat influenza, coronavirus, and pneumonia infections\nA cluster randomised trial of cloth masks compared with medical masks in healthcare workers\nVitamin D supplementation could prevent and treat influenza, coronavirus, and pneumonia infections\nA serological assay to detect SARS-CoV-2 seroconversion in humans\nCOVID-19: protecting health-care workers\nNational UK programme of community health workers for COVID-19 response\nAm I Part of the Cure or Am I Part of the Disease? Keeping Coronavirus Out When a Doctor Comes Home\nRecomendaciones para Profesionales de Atenci\u00f3n Domiciliaria en Cuidados Paliativos. SECPAL-AECPAL\nProtocolo de actuaci\u00f3n SPRL COVID-19. Salud Madrid\nCuidado emocional del personal sanitario ante el COVID-19\nAclaraciones sobre el uso de mascarillas\nPersonal Sanitario. Precauciones a considerar en su domicilio.\n-DIAGN\u00d3STICO:\nSaliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2\nWaiting for Certainty on Covid-19 Antibody Tests \u2014 At What Cost?\nCOVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?\nPrognostic Value of Cardiovascular Biomarkers in COVID-19: A Review\nProcalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis\nBritish Thoracic Society Guidance on Respiratory Follow Up of Patients with a Clinico-Radiological Diagnosis of COVID-19 Pneumonia\nVariation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction\u2013Based SARS-CoV-2 Tests by Time Since Exposure\nA proposed lung ultrasound and phenotypic algorithm for the care of COVID-19 patients with acute respiratory failure\nChest CT for detecting COVID-19: a systematic review and meta-analysis of diagnostic accuracy\nTargets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals\nCOVID-19: False Negatives / Projections for Africa / Predictive Biomarkers\nDevelopment and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19\nInterpreting a covid-19 test result\nAlterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection\nInterpreting Diagnostic Tests for SARS-CoV-2\nCPR in the Covid-19 Era \u2014 An Ethical Framework\nInfectious Diseases Society of America Guidelines on the Diagnosis of COVID-19\nInterpreting Diagnostic Tests for SARS-CoV-2\nCOVID-19 diagnosis and management: a comprehensive review\nClassification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases\nIDSA COVID-19 Antibody Testing Primer\nCovid-19: a remote assessment in primary care\nGlobal Progress on COVID-19. Serology-Based Testing\nEndothelial cell infection and endotheliitis in COVID-19\nFalse-negative results of initial RT-PCR assays for COVID-19: a systematic review.\nResearch Update. Comorbidity and COVID-19. NHS.\nAcute Kidney Injury (AKI) and COVID-19. NHS\nPrediction models for diagnosis and prognosis of Covid-19 infection: systematic review and critical appraisal\nInterpretaci\u00f3n de las pruebas diagn\u00f3sticas frente a SARS-CoV-2. Ministerio de Sanidad, SEIMC e ISCIII\nCOVID-19 outbreak: less stethoscope, more ultrasound\nCovid-19 pandemic and the skin - What should dermatologists know?\nPrediction models for diagnosis and prognosis of Covid-19 infection: systematic review and critical appraisal\nCovid-19: testing times\nThe Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society\nLower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province\nCovid-19: four fifths of cases are asymptomatic, China figures indicate\nA serological assay to detect SARS-CoV-2 seroconversion in humans\nProfiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)\nPositive RT-PCR Test Results in Patients Recovered From COVID-19\nPositive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020\nPoint-of-Care RNA-Based Diagnostic Device for COVID-19\nPerformance of VivaDiagTM COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department\nDiagnostic Testing for the Novel Coronavirus\nBrescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm\nDiagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19\nCombination of RT-qPCR Testing and Clinical Features For Diagnosis of COVID-19 facilitates management of SARS-CoV-2 Outbreak\nAntibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice\nCoronavirus in pregnancy and delivery: rapid review\nProcalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis\nRadiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA\nCoronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know\nManejo COVID-19. H. Ram\u00e7on y Cajal. Infecciosas\nViral load of SARS-CoV-2 in clinical samples\nRecomendaciones de la Sociedad Espa\u00f1ola de Neurolog\u00eda (SEN) en relaci\u00f3n con la p\u00e9rdida de olfato como posible s\u00edntoma precoz de infecci\u00f3n por CoVID-19\nLaboratory testing for coronavirus disease (COVID-19) in suspected human cases. WHO-OMS\nUtilidad de la ecograf\u00eda pulmonar en la enfermedad COVID-19. Medicina Interna H.U.Torrec\u00e1rdenas\nDiagnostic Testing for the Novel Coronavirus\nInternational Pulmonologist's Consensus on COVID-19\nCOVID-19 Science Report: Diagnostics. SSHSPH\nCOVID-19 Prioritization of Diagnostic Testing. IDSA\nUC Infectious Diseases Division. Work up guidance algorrithm\nCorrelation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology\nWell-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19\nPlan asistencial de Medicina Interna COVID-19. HUCA. 22 de marzo\nSistem\u00e1tica de actuaci\u00f3n ante pacientes con PCR negativa y sospecha de infecci\u00f3n por COVID-19.\nRecomendaciones de la SEORL-CCC para la pr\u00e1ctica de la especialidad durante la pandemia de COVID-19. 22 de marzo.\nProtocolo de manejo COVID-19. Hospital Universitario de Getafe\nGu\u00eda pr\u00e1ctica para el manejo de los pacientes ingresados con infecci\u00f3n por SARS-CoV-2. Hospital General Universitario Gregorio Mara\u00f1\u00f3n\nGestaci\u00f3n y coronavirus. Hospital Universitario Central de Asturias\nCriterio de Atenci\u00f3n Cl\u00ednica y de derivaci\u00f3n hospitalaria de pacientes diagnosticados como casos probables de infecci\u00f3n por SARS-CoV-2\nGu\u00eda b\u00e1sica de indicaciones de pruebas de imagen en la infecci\u00f3n COVID-19 (V1. 21/3/2020)\nComunicado de la SEORL-CCC\n-CL\u00cdNICA, COMPLICACIONES Y PRON\u00d3STICO:\numoral Immune Response to SARS-CoV-2 in Iceland\nMortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study\nNeuropathological Features of Covid-19\nMortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study\nCOVID-19: the vasculature unleashed\nCharacterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series\nNeuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019 A Review\nCardiovascular disease and COVID-19\nViral and host factors related to the clinical outcome of COVID-19\nCharacteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy\nCharacteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019\nDeep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome\nAcute kidney injury in patients hospitalized with COVID-19\nThe trinity of COVID-19: immunity, inflammation and intervention\nEuropean Society of Trauma and Emergency Surgery (ESTES) recommendations for trauma and emergency surgery preparation during times of COVID\u201119 infection\nEmergency trauma care during the outbreak of corona virus disease 2019 (COVID-19) in China\nEmergency surgery during the COVID-19 pandemic: what you need to know for practice\nCOVID-19 Infection Implications for Perioperative and Critical Care Physicians\nCOVID-19 - ESSKA guidelines and recommendations for resuming elective surgery\nCardiac Surgery during the COVID-19 Pandemic: Perioperative Considerations and Triage Recommendations\nPulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19\nA need for prone position CPR guidance for intubated and non-intubated patients during the COVID-19 pandemic\nUse of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure\nPotential association between COVID-19 mortality and healthcare resource availability\nRisk factors for severity and mortality in adult COVID-19 inpatients in Wuhan\nPredictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study\nClinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China\nClinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study\nClinical course and mortality risk of severe COVID-19\nSevere Covid-19\nGlobal guidance for surgical care during the COVID-19 pandemic\nA noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2\nAcute kidney injury in patients hospitalized with Covid-19\nThromboembolic risk and anticoagulant therapy in COVID\u201019 patients: Emerging evidence and call for action\nPathological inflammation in patients with COVID-19: a key role for monocytes and macrophages\nImmune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia\nIncidence of venous thromboembolism in hospitalized patients with COVID\u201019\nIncidence of thrombotic complications in critically ill ICU patients with COVID-19\nVenous thromboembolic events in anticoagulated COVID-19 patients\nFibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19\nDevelopment and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19\nCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up\nCOVID-19 and its implications for thrombosis and anticoagulation\nAbnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia\nAcute myocardial injury is common in patients with covid-19 and impairs their prognosis\nImmune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia\nAssociation of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China\nCardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic\nClinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus\nRisk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China\nAssociation of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)\nCharacteristic CT findings distinguishing 2019 novel coronavirus disease (COVID-19) from influenza pneumonia\nAssociation Between Hypoxemia and Mortality in Patients With COVID-19\nD-dimer levels on admission to predict in-hospital mortality in patients with Covid-19\nThromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action\nCoronavirus Infections and Type 2 Diabetes\u2014Shared Pathways with Therapeutic Implications\nThe duration of viral shedding of discharged patients with severe COVID-19\nManagement of Acute Myocardial Infarction During the COVID-19 Pandemic\nSARS-CoV-2 and viral sepsis: observations and hypotheses\nAssociation of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes\nViral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study\nCardiovascular Disease, Drug Therapy,and Mortality in Covid-19\nClinical phenotypes of SARS-CoV-2: Implications for clinicians and researchers\nPulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence\nRelationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients\nThe trinity of COVID-19: immunity, inflammation and intervention\nRole of immunosuppressive therapy in rheumatic diseases concurrent with Covid-19\nCoronavirus Infections and Type 2 Diabetes\u2014Shared Pathways with Therapeutic Implications\nThe duration of viral shedding of discharged patients with severe COVID-19\nDescription and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome\nVariation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs\nRespiratory health in athletes: facing the COVID-19 challenge\nRespiratory Muscle Performance Screening for Infectious Disease Management Following COVID-19: A Highly Pressurized Situation\nSARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes\nCOVID-19 and Older Adults: What We Know\nCoronavirus, COVID-19, SARS\nRisk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China\nPrediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score\nPrediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score\nPrevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID19 Infection\nClinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan\nAssociation of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China\nMyocardial Injury in Patients Hospitalized with COVID-19\nProfile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\nPhysician Deaths from Corona Virus Disease (COVID-19)\nNeutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage\nGastrointestinal Complications in Critically Ill Patients with COVID-19\nComparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational studys\nGuide to Understanding the 2019 Novel Coronavirus\nCovid-19: four fifths of cases are asymptomatic, China figures indicate\nInpatient Care of Patients with COVID-19: A Guide for Hospitalists\nCOVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next\nEvaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections\nAntibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019\nUnique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures\nCharacteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California. JAMA\nCytokine Storm Syndrome\nManagement of COVID-19 Respiratory Distress\nFactors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York City\nCoronavirus as silent killer: recent advancement to pathogenesis, therapeutic strategy and future perspectives\nAssociation of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China\nCharacteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China\nCoronavirus Disease19 in Geriatrics and Long-Term Care: An Update\nAlterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection\nLymphopenia predicts disease severity of COVID-19: a descriptive and predictive study\nSymptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington\nCentral nervous system manifestations of COVID-19: A systematic review\nGuillain\u2013Barr\u00e9 Syndrome Associated with SARS-CoV-2\nPresenting Characteristics, Comorbidities, and Outcomes Among 5.700 Patients Hospitalized With COVID-19 in the New York City Area\nRenin\u2013Angiotensin\u2013Aldosterone System Inhibitors in Patients with Covid-19\nD-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis\nESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic\nCOVID-19 in Hemodialysis Patients: A Report of 5 Cases\nCOVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?\nCytokine release syndrome in severe COVID-19\nInterim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19\nSARS-CoV-2 and viral sepsis: observations and hypotheses\nCorrelation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases\nClinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System\nCovid-19 Does Not Lead to a \u201cTypical\u201d Acute Respiratory Distress Syndrome\nAssociation of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19\nClinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study\nSymptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington\nWell-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19\nCoronavirus: novel coronavirus (COVID-19) infection\nClinical Characteristics of Covid-19 in New York City\nCoronavirus disease 2019 (COVID-19).BMJ Best Practice.\nThe cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality\nCOVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities\nThe Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019\nSmoking is Associated with COVID-19 Progression: A Meta-Analysis\nNovel 2019 Coronavirus SARS-CoV-2 (COVID-19): An Overview for Emergency Clinicians\nClinical observation and management of COVID-19 patients\nTissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series\nPulmonary thrombosis in 2019-nCoV pneumonia?\nIncidence of thrombotic complications in critically ill ICU patients with COVID-19\nHematological findings and complications of COVID-19\nAttention should be paid to venous thromboembolism prophylaxis in the management of COVID-19\nAbnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia\nThe Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease\nNervous system involvement after infection with COVID-19 and other coronaviruses\nCoronavirus infections and type 2 diabetes-shared pathways with therapeutic implications\nRates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens\nImmune Thrombocytopenic Purpura in a Patient with Covid-19\nNeurologic Features in Severe SARS-CoV-2 Infection\nPresymptomatic Transmission of SARS-CoV-2 \u2014 Singapore, January 23\u2013March 16, 2020\nCharacteristics of Health Care Personnel with COVID-19 \u2014United States, February 12\u2013April 9, 2020\nAsymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility \u2014King County, Washington, March 2020\nOncology Practice During the COVID-19 Pandemic\nAwareness, Attitudes, and Actions Related to COVID-19 Among Adults With Chronic Conditions at the Onset of the U.S. Outbreak\nHypertension, the renin\u2013angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19c\nNot Dying Alone \u2014 Modern Compassionate Care in the Covid-19 Pandemic\nThe Variety of Cardiovascular Presentations of COVID-19\nPulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans\nDysregulation of immune response in patients with COVID-19 in Wuhan, China\nNeutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 2 patient cohort and their implications\nACE2 the Janus-faced protein \u2013 from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19\nIntensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations\nDiagnosis and Management of COVID-19 Disease. American Thoracic Society\nPathological study of the 2019 novel coronavirus disease (COVID-19) through post-mortem core biopsies\nSurviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)\nCOVID-19 Autopsies, Oklahoma, USA\nCOVID-19: consider cytokine storm syndromes and immunosuppression\nNeurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China\nInfectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection\nCould Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in geneticallypredisposed subjects?\nDifference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2\nGuidance for Cardiac Electrophysiology During the Coronavirus (COVID-19)\nRenin-Angiotensin System Blockers and the COVID-19 Pandemic\nEstimates of the severity of coronavirus disease 2019: a model-based analysis\nCoronavirus Disease 2019 (COVID-19) and Cardiovascular Disease\nAcute Acro-ischemia in the child at the time of COVID-19\nPractical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected\nScreening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain\nCoronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus\nClinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies\nTreatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma\nPluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure\nCoagulopathy and Antiphospholipid Antibodies in Patients with Covid-19\nTimely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed\nRenin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension\nObesity and its Implications for COVID-19 Mortality\nHypertension and its severity or mortality in Coronavirus Disease 2019\nEffects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis\nDiabetes patients with COVID-19 need better blood glucose management in Wuhan, China\nCOVID-19 and the ReninQ1 Angiotensin System\nCOVID 19 and the Patient with Obesity \u2013 The Editors Speak Out\nClinical considerations for patients with diabetes in times of COVID-19 epidemic\nCOVID-19 and the Heart\nAn algorithm for managing QT prolongation in Coronavirus Disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine\nUrgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease Q2 Q1 19 (COVID-19). Mayo Clinic\nPandemic palliative care: beyond ventilators and saving lives\nProtocolo de manejo y tratamiento de los pacientes cr\u00edticos con neumon\u00eda grave por COVID-19. Hospital Vall d'Hebr\u00f3n\nRecent advances in the detection of respiratory virus infection in humans\u201d\nReview of \u201cViral dynamics in mild and severe cases of COVID-19\u201d\nViral dynamics in mild and severe cases of COVID-19\nCovid-19 in South Korea \u2014 Challenges of Subclinical Manifestations\nCOVID\u201019: Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society\u2010led International Task Force\nRenin-Angiotensin System Blockers and the COVID-19 Pandemic At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers\nBaseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy\nClinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China\nUrgencia respiratoria en pacientes COVID-19. Hospital Universitario Infanta Cristina\nClinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. OMS\nThe effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study\nProceso de Atenci\u00f3n al Final de la Vida. Hospital General Universitario Gregorio Mara\u00f1\u00f3n\nAssociation of QT-Prolonging Medications With Risk of Autopsy-Defined Causes of Sudden Death\nCardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)\nCardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis\nPandemic palliative care: beyond ventilators and saving lives\nProtocolo de manejo cl\u00ednico de los pacientes infectados por Coronavirus CoV-2 (COVID-19). SERGAS. \u00c1rea Sanitaria de Coru\u00f1a y Cee.\nCOVID-19 and Diabetes: can DPP4 inhibition play a role?\nEffects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis\nCOVID-19: Knowns, Unknowns, and Questions\nEnfermedades autoinmunes y COVID-19. Experiencias en el manejo de estos pacientes del Hospital Clinic de Barcelona\nLiver injury during highly pathogenic human coronavirus infections\nClinical Features of COVID-19-Related Liver Damage\nLiver injury in COVID-19: management and challenges\nRecomendaciones ante una parada cardiaca durante la pandemia de COVID-19\nPragmatic Recommendations for Intubating Critically Ill Patients with Suspected COVID-19\nThrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis\nRenin\u2013Angiotensin\u2013Aldosterone System Inhibitors in Patients with Covid-19\nClinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study\nSurviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)\nCytokines Storm Syndrome (CSS)\nCOVID-19 infection and rheumatoid arthritis: Faraway, so close!\nCOVID-19: the new challenge for rheumatologists\nManagement of Critically Ill Adults With COVID-19\nAbnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia\nPhysiotherapy Management for COVID-19 in the Acute Hospital Setting: Recommendations to guide clinical practice\nFunctional exhaustion of antiviral lymphocytes in COVID-19 patients\nImmunosuppression for hyperinflammation in COVID-19: a doubleedged sword?\nRecomendaciones para el manejo de la Miastenia Gravis (MG) y el s\u00edndrome miast\u00e9nico de Lambert-Eaton (LEMS) durante la pandemia de COVID-19\nCOVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal\nCOVID-19: consider cytokine storm syndromes and immunosuppression\nImplicaciones de la pandemia por COVID-19 para el paciente con insuficiencia card\u00edaca, trasplante card\u00edaco y asistencia ventricular. Recomendaciones de la SEC\nRecomendaciones para manejo de pacientes con infecci\u00f3n por COVID-19 en el contexto de una intervenci\u00f3n quir\u00fargica urgente o electiva. Asociaci\u00f3n Espa\u00f1ola de Cirujanos (AEC)\nRecomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infecci\u00f3n por SARSCoV-2\nClinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study\nClinical associations of renal involvement in ANCA-associated Vasculitis\nTeleconferencia 10/03/2020 UCI de Lombardia (Milan,Monza,Bergamo,Pavia,Lecco) \u00e1rea de m\u00e1xima difusi\u00f3n de COVID-19 en Italia desde febrero 2020\nClinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. WHO\nSurviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)\nClinical Characteristics of Coronavirus Disease 2019 in China. TNEJOM\nCharacteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China\nCharacteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State\nAsymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. JMII\nConsideraciones sobre el abordaje invasivo de la cardiopat\u00eda isqu\u00e9mica y estructural durante el brote de coronavirus COVID-19. Documento de consenso de la Asociaci\u00f3n de Cardiolog\u00eda Intervencionista y la Asociaci\u00f3n de Cardiopat\u00eda Isqu\u00e9mica y Cuidados Agudos Cardiovasculares de la Sociedad Espa\u00f1ola de Cardiolog\u00eda\nCOVID-19 e inhibidores de la enzima convertidora de angiotensina y bloqueadores del receptor de angiotensina \u00bfCu\u00e1l es la evidencia? JAMA\nSARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Article CELL\nCOVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?\nRecomendaciones del Grupo de Trabajo de VMNI de la Sociedad Espa\u00f1ola de Urgencias y Emergencias respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infecci\u00f3n por SARS-CoV-2\nRisk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China\nGu\u00edas de manejo en terapia intensiva\nManejo del SDRA de la Sociedad Catalana de Cr\u00edticos\nS\u00edndrome de Distr\u00e9s Respiratorio Agudo: Abordaje basado en evidencia\nProtocolo de atenci\u00f3n a pacientes en situaci\u00f3n de gravedad o \u00faltimos d\u00edas y \u00e9xitus en la crisis del COVID-19. Hospital Universitario La Paz de Madrid.\nA Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19\nClinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study\nRecomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infecci\u00f3n por SARSCoV-2\n-TRATAMIENTO:\nProceso Asistencial Integrado para la atenci\u00f3n a las personas afectadas por SARS-CoV-2 (SACYL)\nHistorically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study\nDexamethasone in Hospitalized Patients with Covid-19 \u2014 Preliminary Report\nTocilizumab in patients with severe COVID-19: a retrospective cohort study\nDirect oral anticoagulant plasma levels\u2019 striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience\nUse of renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study\nHydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review\nHydroxychloroquine for the Prevention of Covid-19 \u2014 Searching for Evidence\nA Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19\nExpression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis\nCOVID-19, hypertension and cardiovascular diseases: Should we change the therapy?\nExperimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study\nThe Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19\nAnakinra for severe forms of COVID-19: a cohort study\nScientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19\nCaution against corticosteroid-based COVID-19 treatment\nConsiderations in prophylaxis and treatment of VTE in COVID-19 Patients\nCOVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital\nVitamin D supplementation could possibly improve clinical outcomes of patients infected with Coronavirus-2019 (COVID2019)\nThe role of vitamin D in the prevention of coronavirus disease 2019infection and mortality\nRoutine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019\nPotential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson\u2019s Disease\nPerspective: improving vitamin D status in the management of COVID-19\nCOVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19\nCOVID-19 rapid evidence summary: Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19\nCOVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers\nTreatment algorithm for COVID-19: a multidisciplinary point of view\nA Review of SARS-CoV-2 and the Ongoing Clinical Trials\nOngoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews\nRemdesivir for the Treatment of Covid-19 \u2014 Preliminary Report\nHydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis\nYNHHS Initial Treatment Algorithm for Hospitalized ADULTS with Non\u2013Severe* COVID-19\nAssociation of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State\nTreatment of Community-Acquired Pneumonia During the Coronavirus Disease 2019 (COVID-19) Pandemic\nEfficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis\nCirculating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin\u2013angiotensin\u2013aldosterone inhibitors\nDirect oral anticoagulant plasma levels\u2019 striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience\nCoronavirus Disease 2019 (COVID-19) Treatment Guidelines\nNon-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection\nComplement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases\nAttention should be paid to venous thromboembolism prophylaxis in the management of COVID-19\nAssociation of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)\nAnticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\nInterleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study\nSilencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome\nAssociation of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State\nIvermectin as a potential COVID-19 treatment from the pharmacokinetic point of view\nTriple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial\nCardiovascular Disease, Drug Therapy, and Mortality in Covid-19\nEffect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection\nVademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020\nCoronavirus Disease 2019 Treatment: A Review of Early and Emerging Options\nCurrent Drugs with Potential for Treatment of COVID-19: A Literature Review\nCOVID-19 and its implications for thrombosis and anticoagulation\nImpact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis\nAssociation of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19\nObservational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19\nA Trial of Lopinavir\u2013Ritonavir in Covid-19\nUsefulness of Ivermectin in COVID-19 Illness\nAssociation of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)\nHydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation\nAssessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit\nRisk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)\nCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up\nFinding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness\nHypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge\nRenin\u2013Angiotensin\u2013Aldosterone System Blockers and the Risk of Covid-19\nThromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidenceand call for action\nTreatment of patients with nonsevere and severe coronavirus disease 2019: an evidencebased guideline\nThe Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19\u2014First, Do No Harm\nCurrent pharmacological treatments for COVID-19: what\u2019s next?\nInnovation in Response to the COVID-19 Pandemic Crisis\nDoes high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2?\nChloroquine and hydroxychloroquine in the context of COVID-19\nRemdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial\nCoronavirus Disease 2019 Treatment: A Review of Early and Emerging Options\nCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up\nYNHHS Initial Treatment Algorithm for Hospitalized ADULTS with Non\u2013Severe COVID-19\nRecomendaciones sobre el tratamiento antitrombotico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Espa\u00f1ola de Cardiolog\u00eda\nManagement of COVID-19 Respiratory Distress\nCurrent Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19\nMesenchymal Stem Cell Therapy for COVID-19: Present or Future\nEffect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. A Randomized Clinical Trial\nNIH issues treatment guidelines for COVID-19\nCOVID-19. Survival Guide - 1st Edition. McMaster University, Department of Medicine Hamilton, ON, Canada\nRationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019\nHydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial\nCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up\nRecomendaciones de tromboprofilaxis y tratamiento antitromb\u00f3tico en pacientes con COVID-19. SETH\nDeployment of convalescent plasma for the prevention and treatment of COVID-19\nConsiderations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment\nResearch Update Therapies COVID19. University Hospitals Birmingham. NHS Foundation Trust\nAssessment of Evidence for COVID-19-Related Treatments: Updated 4/17/2020\nTromboprofilaxis en infecci\u00f3n por COVID-19. SERGAS\nAngiotensin receptor blockers as tentative SARS-CoV-2 therapeutics\nWill Complement Inhibition be the New Target in Treating COVID-19\nMount Sinai COVID-19 Anticoagulation Algorithm\nSARS-CoV-2 and COVID-19. Treatment: Lopinavir-Ritonavir. University of Washington.\nSARS-CoV-2 and COVID-19. Treatment: Remdesivir. University of Washington.\nSummary on compassionate use Remdesivir Gilead. EMA.\nRemdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites\nRemdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency\nMechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir\nRemdesivir, la esperanza antiviral frente al SARS-CoV-2. Revista Espa\u00f1ola de Quimioterapia\nRemdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence\nCurrent knowledge about the antivirals remdesivir (GS-5734) and GS441524 as therapeutic options for coronaviruses\nCompounds with therapeutic potential against novel respiratory 2019 coronavirus\nRemdesivir como potencial terapia frente al COVID-19. Servicio Navarro de Salud\nCompassionate Use of Remdesivir for Patients with Severe Covid-19\nCOVID-19 Drug Therapy\nNutrition Therapy in the Patient with COVID-19 Disease Requiring ICU Care\nNutrition and Hydration: Key Weapons in the Fight Against COVID-19\nRationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019\nInteractions with experimental COVID-19 therapies\nNo evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial\nDrug Evaluation during the Covid-19 Pandemic\nPotential antiviral mechanism of hydroxychloroquine in COVID-19 and further extrapolation to celecoxib (Celebrex\u00d2) for future clinical trials.\nThe FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro\nCan we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?\nAnticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\nProtocolo de tromboprofilaxis en pacientes con infecci\u00f3n COVID-19 del Hospital Universitario La Paz de Madrid\nClinical Outcomes of Hydroxychloroquine in Hospitalized Patients with COVID-19: A Quasi-Randomized Comparative Study\nClinical trials on drug repositioning for COVID-19 treatment\nRemdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence\nCompassionate Use of Remdesivir for Patients with Severe Covid-19\nUrgent Safety Notice Use of SGLT2 inhibitors during the Covid-19 Crisis 03.04.2020\nISTH interim guidance on recognition and management of coagulopathy in COVID-19\nAnticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\nCoronavirus (COVID-19) Infection in Pregnancy\nInterim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19\n\u201cLess is More\u201d in mechanical ventilation\nCOVID-19 pneumonia: different respiratory treatment for different phenotypes?\nAssessment of Evidence for COVID-19-Related Treatments: Updated 4/8/2020\nInteractions with experimental COVID-19 therapies. Liverpool University\nShould chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review\nChloroquine and hydroxychloroquine in Covid-19\nInformation for Clinicians on Therapeutic Options for Patients with COVID-19\nAntihypertensive drugs and risk of COVID-19?\nEffective Treatment of Severe COVID-19 Patients with Tocilizumab\nTowards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients\nDrug Induced QTc Prolongation. COVID-19\nThe FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro\nA brief review of antiviral drugs evaluated in registered clinical trials for COVID-19\nSystematic Review of the Registered Clinical Trials of Coronavirus Disease 2019 (COVID-19)\nCollecting and evaluating convalescent plasma for COVID-19 treatment: why and how\nBarrier Enclosure during Endotracheal Intubation\nPrograma de manejo ambulatorio de pacientes con neumon\u00eda COVID-19 leve y bajo riesgo de complicaciones. Hospital Universitario Infanta Cristina\nConsensus guidelines for managing the airway in patients with COVID-19\nUse of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know\nCovid-19: what treatments are being investigated?\nCovid-19: FDA approves use of convalescent plasma to treat critically ill patients\nManejo de pacientes con COVID19. Hospital Universitario de Getafe\nTratamiento Antiviral e Inmunomodulador de la Infecci\u00f3n por SARS-CoV-2. Protocolo HUyP La Fe (Valencia). 2 de marzo de 2020.\nOn the use of corticosteroids for 2019-nCoV pneumonia\nCovid-19 y personas con enfermedades neuromusculares: Posicionamiento y recomendaciones de la Sociedad Mundial en Enfermedades Musculares (World Muscle Society)\nImpact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand\nInteractions with experimental COVID-19 therapies. University of Liverpool\nInteractions with experimental COVID-19 therapies\nEvaluating the drug-drug interaction risk of experimental COVID-19 therapies\nAntimal\u00e1ricos para el tratamiento de COVID-19\nYNHHS Treatment Algorithm for Hospitalized Patient with Non\u2013Severe COVID-19\nConsiderations for Pharmacologic Treatments of Patients with Confirmed COVID-19 testing for the PICU and general inpatient unit (GIU)\nDexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial\nConvalescent Plasma to Treat COVID-19 Possibilities and Challenges\nPlan de trabajo \"Gu\u00eda r\u00e1pida del Protocolo COVID Hospital IFEMA. Marzo de 2020\nAnticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\nGu\u00eda de tratamiento de adultos con enfermedad por Coronavirus (SARS-CoV-2). Hospital Universitario 12 de Octubre. Versi\u00f3n 9.0 (27 de Marzo de 2020)\nClinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study\nHydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial\nUrgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19\nTreating COVID-19\u2014Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics\nRenin-Angiotensin System Blockers and the COVID-19 Pandemic At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers\nNetwork-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2\nRevisi\u00f3n del uso de terapias biol\u00f3gicas en el S\u00edndrome de Distress Respiratorio Agudo secundario a la infecci\u00f3n por COVID-19 (SARS-CoV-2)\nRecomendaciones de fisioterapia respiratoria y ejercicio f\u00edsico para personas afectadas por el COVID-19. CPFCM\nDeclaraci\u00f3n HFSA/ACC/AHA aborda las preocupaciones sobre el uso de antagonistas RAAS en COVID-19\nA systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19\nInterferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory SyndromeA Preliminary Study\nEffective Treatment of Severe COVID-19 Patients with Tocilizumab\nVentilaci\u00f3n Mec\u00e1nica No Invasiva en COVID-19. Hospital del Henares\nTratamiento de la infecci\u00f3n por Coronavirus CoV-2 (COVID-19). Hospital Ram\u00f3n y Cajal\nF\u00e1rmacos estudiados para combatir el SARS-CoV-2\nMGH Treatment Guide for Critically Ill Patients witth COVID-19\nManejo al alta del paciente COVID-19. H.R.U. de M\u00e1laga\nA Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19\nHydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial\nEUSEM Position paper on Emergency Medical Systems response to COVID-19\nGu\u00eda de Tratamiento COVID-19 Hospital 12 de Octubre\nFair Allocation of Scarce Medical Resources in the Time of Covid-19. The New England Journal of Medicine\nThe Toughest Triage \u2014 Allocating Ventilators in a Pandemic. The New England Journal of Medicine\nMassachusetts General Hospital COVID-19 Treatment Guidance\nAssessment of Evidence for COVID-19-Related Treatments. ASHP\nEffective Treatment of Severe COVID-19 Patients with Tocilizumab\nManejo farmacol\u00f3gico de trastornos psic\u00f3ticos en personas mayores con tratamiento de la infecci\u00f3n por COVID19: interacciones y recomendaciones terap\u00e9uticas\nEsquema Terap\u00e9utico Simplificado_ manejo hospitalario de pacientes con infecci\u00f3n confirmada por SARS-CoV-2 en Medicina Interna del HUCA. 22 de marzo de 2020\nTratamiento adultos COVID-19. Hospital Universitario Guadalajara\nProtocolo tratamiento COVID del Mount Sina\u00ed\nGu\u00eda de tratamiento COVID-19 del Hospital Universitario 12 de Octubre\nEstudio sobre el tratamiento con hidroxicloroquina y a\u00f1adiendo a \u00e9sta azitromicina\nEsquema de manejo del paciente COVID-19. Hospital Universitario de Fuenlabrada.\nCovid-19 \u2014 The Search for Effective Therapy. The New England Journal of Medicine\nInteractions with Experimental COVID-19 Therapies\nTratamiento del COVID-19. Osakidetza\nTratamiento de la infecci\u00f3n por Coronavirus (COVID-19) CoV-2. Hospital Universitario Ram\u00f3n y Cajal. Versi\u00f3n 2.0 d\u00eda 13 de marzo de 2020\nPlan de contingencia para los servicios de Medicina Intensiva frente a la pandemia del COVID-19. SEMICYUC-SEMI\n-OTROS:\nRepurposed Antiviral Drugs for Covid-19\u2014Interim WHO Solidarity Trial Results\nPutting the Public Back in Public Health \u2014 Surveying Symptoms of Covid-19\nCoronavirus disease 2019 (COVID-19): A literature review\nNew Criteria for Lupus\nEstimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study\nOn the brighter side of COVID-19 induced Lockdown: Devising the collateral methods to provide Ayurveda consultation during impasse\nCOVID-19 and Racial/Ethnic Disparities\nViolence against women during covid-19 pandemic restrictions\nOccurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers: rapid review and meta-analysis\nThe Early Natural History of SARS-CoV-2 Infection: Clinical Observations From an Urban, Ambulatory COVID-19 Clinic\nGender Differences in Patients With COVID-19: Focus on Severity and Mortality\nCovid-19 \u2014 A Reminder to Reason\nCoronavirus: The Hammer and the Dance\nA real-time dashboardof clinical trials for COVID-19\nInnovation and Transformation in the Response to Covid-19: Seven Areas Where Clinicians Need to Lead\nCOVID-19: The Worst Days of Our Careers\nDisease Control, Civil Liberties, and Mass Testing \u2014 Calibrating Restrictions during the Covid-19 Pandemic\nWhat I learnt from studying doctors\u2019 mental health over 20 years\u2014an essay by Jenny Firth-Cozens\nSusceptibility of ferrets, cats, dogs, and other domesticated animals to SARS\u2013coronavirus 2\nCovid-19 and Health Care\u2019s Digital Revolution\nGlobal coalition to accelerate COVID-19 clinical research in resource-limited settings\nUnderstanding and Addressing Sources of Anxiety Among Health Care Professionals During the COVID-19 Pandemic\nThe Toughest Triage \u2014 Allocating Ventilators in a Pandemic\nConsideraciones SEIMC para dar de alta a personal sanitario con COVID-19\nFair Allocation of Scarce Medical Resources in the Time of Covid-19\nCertificaciones de Defunci\u00f3n de fallecidos por causas naturales, y en especial en los casos con Covid-19 o sospecha de infecci\u00f3n por Covid-19. OMC.\nThe economics of a pandemic: the case of Covid-19\nCOVID-19: fighting panic with information\nCoronavirus: the spread of misinformation\nThe psychological impact of quarantine and how to reduce it: rapid review of the evidence\nParenting in a time of COVID-19\nThe art of medicine COVID-19: the medium is the message\nVirtually Perfect? Telemedicine for Covid-19\nImpact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand\nProtocolo para la comunicaci\u00f3n telef\u00f3nica de malas noticias a familiares con Coronavirus en situaci\u00f3n de \u00faltimos d\u00edas. Equipo de Soporte de Cuidados Paliativos del H.U. 12 de Octubre\nComunicado de SEMI, semFYC, SEMICYUC y SEPAR sobre MIR ante pandemia COVID-19", "language": null, "image": null, "pagetype": null, "links": ["#main-content", "/", "https://www.instagram.com/sociedad_semi/", "//twitter.com/Sociedad_SEMI", "//www.facebook.com/Residentes-de-Medicina-Interna-de-Espa\u00f1a-156272471208663/", "https://es.linkedin.com/company/sociedad-espa\u00f1ola-de-medicina-interna", "https://www.youtube.com/channel/UC59eVtNrB9yMJn8ym4xVLVw", "/rss", null, "/user/password", "/", "/quienes/semi/junta", "/quienes/semi/junta", "/quienes/femi/presentacion", "/quienes/efim/que-es", "/quienes/relaciones-internacionales", "/quienes/semi/la-pregunta-semi-del-mes", "/quienes/semi/marco-etico", "/quienes/semi/himno", "/quienes/pregunta-al-presidente", "/quienes/registro", "/quienes/documentacion", "/contacto", "/sociedades", "/sociedades/sademi", "/sociedades/aragon", "/sociedades/samin", "/sociedades/socami", "/sociedades/socalmi", "/sociedades/scbmi", "/sociedades/smicv/sociedad/junta-directiva", "/sociedades/sexmi", "/sociedades/sogami", "https://www.fesemi.org/sociedades/somimaca/home", "/sociedades/somimur", "/quienes/registro", "/grupos", "/grupos/alcohol/noticias", "/grupos/asistencia-compartida/noticias", "/grupos/bioetica/noticias", "/grupos/diabetes/noticias", "/grupos/cronicidad-pluripatologia/noticias", "/grupos/cuidados-paliativos/quienes-somos", "/grupos/ecografia/noticias", "/grupos/educacion/quienes-somos", "/grupos/tromboembolica/noticias", "/grupos/autoinmunes/noticias", "/grupos/infecciosas/noticias", "/grupos/minoritarias/noticias", "/grupos/epoc/noticias", "/grupos/formacion/noticias", "/grupos/gestion/noticias", "/grupos/hospitalizacion/noticias", "/grupos/medicina-digital", "/grupos/cardiaca/noticias", "/grupos/osteoporosis/noticias", "/grupos/vascular/noticias", "/grupos/urgencias/noticias", "/grupos/seccion-de-enfermeria/quienes-somos", "/recursos-semi", "/auspicios/reglamento", "/congresos/congresos-semi/proximos", "/congresos/congresos-semi/proximos", "/congresos/reuniones/proximas", "https://www.fesemi.org/congresos/webinars-semi-femi", "/congresos/reuniones-autonomicas/proximas", "/congresos/efim/proximos", "/congresos/otros/proximos", "/congresos/ponencias", "/congresos/calendario", "/informacion-pacientes/buscar-enfermedad", "/formacion/campus", "/investigacion/becas", "/investigacion/becas", "/investigacion/ayudas", "/publicaciones/buscador", "/publicaciones/revista-clinica/noticias", "/publicaciones/revista-clinica/reconocimientos-revisores-rce", "/publicaciones/revista-clinica/noticias", "http://www.revclinesp.es/es/ahead-of-print/", "http://www.revclinesp.es/", "/publicaciones/revista-clinica/archivo", "/publicaciones/revista-clinica/historico", "https://www.fesemi.org/publicaciones/semi/reccmi", "https://www.fesemi.org/publicaciones/semi/spanish-j-med", "/publicaciones/buscador", "/publicaciones/semi/protocolos", "/publicaciones/semi/guias", "/publicaciones/semi/consensos", "/publicaciones/buscador", "/publicaciones/efim/ejim", "/publicaciones/efim/ejim", "/publicaciones/efim/ejcrim", "/publicaciones/hospital-del-futuro", "/publicaciones/otras", "/publicaciones/bibliografia-comentada", "/informacion/enlaces/guias-clinicas", "/publicaciones/declaracion-malaga-2022", "/semi-excelente/recertificacion", "https://www.fesemi.org/quienes/semi/proyecto-semi-excelente", "https://www.fesemi.org/quienes/semi/acreditados", "https://www.fesemi.org/recertificacion", "/informacion/bolsa-trabajo", "/informacion/bolsa-trabajo", "/informacion/bolsa-trabajo/publicacion-de-ofertas-de-empleo", "/informacion/herramientas", "/informacion/enlaces/revistas", "/contacto", "/informacion/multimedia/imagenes/2021", "/comunicacion", "https://www.fesemi.org/comunicacion/boletines-semi", "https://www.fesemi.org/informacion/prensa/semi", "https://www.fesemi.org/informacion/prensa/2020", "https://www.fesemi.org/redes-sociales-de-semi", "https://www.fesemi.org/informacion/multimedia/imagenes/2021", "https://www.fesemi.org/contacto-de-prensa", "https://www.fesemi.org/documentos-de-interes", "https://medicinainternaaltovalor.fesemi.org/generalidades/bienvenid-al-blog-una-medicina-interna-alto-valor/", null, "https://www.facebook.com/sharer/sharer.php?u=https://www.fesemi.org/canal-semi-para-profesionales-covid-19&title=Canal SEMI COVID-19 para Profesionales", "http://twitter.com/intent/tweet?url=https://www.fesemi.org/canal-semi-para-profesionales-covid-19&text=Canal SEMI COVID-19 para Profesionales", "http://www.linkedin.com/shareArticle?mini=true&url=https://www.fesemi.org/canal-semi-para-profesionales-covid-19&title=Canal SEMI COVID-19 para Profesionales", "/", "https://covid19.isciii.es/", "https://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos.htm", "http://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/InformesCOVID-19.aspx", "https://lnkd.in/eCqwmu6", "https://www.bmj.com/<span class='finded'>coronavirus", "https://lnkd.in/ecvvMH9", "https://lnkd.in/eAHguDq", "https://covidreference.com/es", "https://www.fesemi.org/foros/canal-profesional-covid-19-semi", "mailto:oscar.veloso@fesemi.org", "https://www.fesemi.org/guardiaapp", "https://twitter.com/Sociedad_SEMI?ref_src=twsrc%5Etfw", "https://www.instagram.com/sociedad_semi/", "//twitter.com/Sociedad_SEMI", "//www.facebook.com/Residentes-de-Medicina-Interna-de-Espa\u00f1a-156272471208663/", "https://es.linkedin.com/company/sociedad-espa\u00f1ola-de-medicina-interna", "https://www.youtube.com/channel/UC59eVtNrB9yMJn8ym4xVLVw", "/rss", "https://stamp.wma.comb.es/es/seal/2489", "mailto:semi@fesemi.org?subject=Contacto%20desde%20www.fesemi.org", "mailto:femi@fesemi.org?subject=Contacto%20desde%20www.fesemi.org", "/", "/quienes/semi/junta", "/quienes/registro", "/grupos", "/recursos-semi", "/auspicios/reglamento", "/congresos/congresos-semi/proximos", "/informacion-pacientes/buscar-enfermedad", "/formacion/campus", "/investigacion/becas", "/publicaciones/buscador", "/semi-excelente/recertificacion", "/informacion/bolsa-trabajo", "/comunicacion", "/contacto", "/aviso-legal", "/aviso-pacientes", "/financiacion", "/politica-cookies", "/privacidad", "/propiedad-intelectual", "https://stamp.wma.comb.es/es/seal/2489", "https://www.healthonnet.org/HONcode/Spanish/?HONConduct111556", "http://www.iberpixel.com/"]}